Painless bronchoscopy
Conditions
Interventions
Propofol group (C group):Intravenous administration of alfentanil 5 µg/kg, followed by slow intravenous injection of propofol 1.5 mg/kg (injection time within 60 s)
intraoperative additional dose of propofol 0.5 mg/kg according to patient response
if MOAA/S score >1, additional dose of propofol 1.5 mg/kg
Fospropofol disodium group (F group):Intravenous administration of alfentanil 5 µg/kg, followed by slow intravenous injection of fospropofol disodium 10 mg/kg (injection time within 60 s)
intraoperative additional dose of fospropofol disodium 2.0 mg/kg according to patient response
if MOAA/S score >1, additional dose of fospropofol disodium 2.0 mg/kg
Sponsors
The Second Hospital of Jiaxing
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >=65 years, any gender; 2. Planning to undergo fibreoptic bronchoscopy examination or treatment under sedation anaesthesia; 3. American Society of Anesthesiologists (ASA) classification of I–III; 4. Stable vital signs before surgery with no significant signs of respiratory distress; 5. Able to understand the study content and sign the informed consent form (or have it signed by a legal representative).
Exclusion criteria
Exclusion criteria: 1. Those allergic to propofol, fospropofol disodium, alfentanil, or other drugs used in the study; 2. Those with severe heart, lung, liver, or kidney dysfunction (such as severe heart failure, respiratory failure, liver or kidney failure); 3. Those with significant airway management difficulties or severe airway stenosis; 4. Those with central nervous system diseases, severe mental disorders, or cognitive impairments who cannot cooperate with sedation assessment; 5. Those with obvious preoperative hypoxemia (SpO2 <90%) or requiring continuous oxygen therapy; 6. Those with a history of severe adverse reactions to sedation and anaesthesia or anaesthesia-related complications; 7. Other conditions deemed unsuitable for inclusion in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypoxaemia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Low blood pressure;Time from stopping medication to eye opening, time from stopping medication to recovery of orientation, and time leaving the recovery area;Injection pain, nausea and vomiting, agitation;Mean arterial pressure, heart rate and oxygen saturation before anaesthesia induction (T0), at MOAA/S score <=1 (T1), at laryngoscope insertion to vocal cords (T2), 5 minutes after start of laryngoscop; | — |
Countries
China
Contacts
Public ContactXu Hai
The Second Hospital of Jiaxing
Outcome results
None listed